Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet‐induced metabolic dysfunction and non‐alcoholic fatty liver disease in mice

• Published in: British journal of pharmacology Vol. 177; no. 2; pp. 239 - 253
• Main Authors: Chiang, Hao, Lee, Jinq‐Chyi, Huang, Hsiu‐Chen, Huang, Hsing, Liu, Hui‐Kang, Huang, Cheng
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.01.2020; John Wiley and Sons Inc
• Subjects: Adipose Tissue - drug effects; Adipose Tissue - metabolism; Adipose Tissue - pathology; Animals; Biomarkers - blood; Blood Glucose - drug effects; Blood Glucose - metabolism; Body weight gain; Cell Line; Diabetes; Diabetes mellitus; Diet, High-Fat; Dietary supplements; Disease Models, Animal; Drug therapy; Dyslipidemias - etiology; Dyslipidemias - metabolism; Dyslipidemias - prevention & control; Energy Metabolism - drug effects; Fatty liver; Glucose; Glucose metabolism; Glucose Metabolism Disorders - etiology; Glucose Metabolism Disorders - metabolism; Glucose Metabolism Disorders - prevention & control; High fat diet; Humans; Hyperglycemia; Hyperlipidemia; Hypertrophy; Insulin; Insulin Resistance; Lipids - blood; Liver - drug effects; Liver - metabolism; Liver - pathology; Liver diseases; Male; Metabolic disorders; Metabolic Syndrome - etiology; Metabolic Syndrome - metabolism; Metabolic Syndrome - pathology; Metabolic Syndrome - prevention & control; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease - etiology; Non-alcoholic Fatty Liver Disease - metabolism; Non-alcoholic Fatty Liver Disease - pathology; Non-alcoholic Fatty Liver Disease - prevention & control; Obesity; Oleic acid; Oxidation; Phosphorylation; Research Paper; Research Papers; Sodium-glucose cotransporter; Sodium-Glucose Transporter 2 - metabolism; Sodium-Glucose Transporter 2 Inhibitors - pharmacology
• ISSN: 0007-1188; 1476-5381; 1476-5381
• DOI: 10.1111/bph.14859

Background and Purpose Non‐alcoholic fatty liver disease (NAFLD), including non‐alcoholic steatohepatitis, is closely related to metabolic diseases such as obesity and diabetes. Despite an accumulating number of studies, no pharmacotherapy that targets NAFLD has received general approval for clinica...